Targeting the mosquito parasites that cause malaria, rather than mosquitoes themselves, may be a better way of preventing the disease

Publicly released:
Australia; International; NSW
CC-0. https://picryl.com/media/anopheles-gambiae-mosquito-feeding-1354p-lores-11e8ee
CC-0. https://picryl.com/media/anopheles-gambiae-mosquito-feeding-1354p-lores-11e8ee

Targeting the mosquito parasite, Plasmodium falciparum, may be a more effective way of preventing malaria than targeting the mosquitoes themselves, according to international and Aussie scientists. The vast majority (90%) of malaria cases are not caused directly by mosquitoes, but by this parasite, so the team set out to test antimalarial compounds that target its genes and can be applied to mosquito nets. They identified 22 compounds that were the most effective in killing the parasite, all of which are simple, cheap to produce, and could be manufactured at scale. When testing these on mosquito nets, the team found the most effective compound killed 100% of parasites within six minutes of contact with the compound-covered nets, and the effects lasted for a year. Additional lab tests found the compound was just as effective against parasites in mosquitoes that were resistant to insecticides. Applying the compound to nets in countries where malaria occurs could help reduce cases of the deadly disease, the authors conclude.

Media release

From: Springer Nature

Effective new antimalarial targets parasites

Newly discovered compounds that aid in reducing the transmission of malaria by directly targeting and killing the disease-causing parasites in mosquitoes are described in Nature this week. When applied to bed nets, the antimalarials offer an economic and long-lasting alternative to current insecticide-based measures.

More than half a million people die each year from malaria. Although insecticide-treated nets have largely reduced malaria cases, their continued effectiveness is challenged by widespread insecticide resistance. Previous research suggests that targeting the parasite Plasmodium falciparum in the mosquito, which causes 90% of human malaria cases, with antimalarial drugs could be an effective way to mitigate this challenge.

To further explore this approach, Alexandra Probst and colleagues identified the most essential parts of the parasite’s genes to target with antimalarial drugs. After compiling a large library of antimalarial compounds, including some in potential development for human use, the authors found and tested 22 of the most effective at inhibiting the malaria parasite’s development in the mosquito. The discovered compounds were notably simple, easily scalable and cheap to synthesize. The most effective compound killed 100% of parasites present in mosquitoes within six minutes of contact with bed net-like material impregnated with the compound. This remained the case when tested on lab-derived insecticide-resistant mosquitoes. The effect of the compounds in the nets also lasted for a year, demonstrating their long-term functionality and potency.

The authors state that future studies into compounds that do not share the targets of clinically used antimalarials are needed. Additionally, the antimalarial-treated nets should be tested in combination with the currently used insecticide-treated ones to confirm their hypothesized complementary effectiveness. The authors conclude that this previously untapped approach could reduce human malaria cases, especially in the face of insecticide resistance.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends
Journal/
conference:
Nature
Research:Paper
Organisation/s: The University of New South Wales, Harvard T. H. Chan School of Public Health, USA
Funder: F.C. is funded by the Howard Hughes Medical Institute (HHMI) as an HHMI Investigator, by the National Institute of Health (NIH) (grants R01AI148646 and R01AI153404) and by an Open Philanthropy and Good Venture Foundation grant (GV673604528). A.S.P. was funded for a portion of this study by the Fujifilm Fellowship Program as a fellowship recipient. S.Y. was funded by the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Flexible Talent Mobility Account (FTMA) award administered through Imperial College London as an award recipient. M.K.R. was funded by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Program Award i01 BX003312 and VA Research Career Scientist Award 14S-RCS001, by NIH R01AI100569 and R01AI141412, and by the US Department of Defense Peer Reviewed Medical Research Program PR181134. This publication includes data generated at the University of California San Diego Institute for Genomic Medicine Genomics Center using an Illumina NovaSeq 6000 instrument that was purchased with funding from an NIH SIG grant (S10 OD026929) and at the OHSU Medicinal Chemistry Core (Research Resource ID: SCR 019048).
Media Contact/s
Contact details are only visible to registered journalists.